Memo; Statistical Review AFCAPS/TEXCAPS
Date:
Between: Mary Parks, M.D., Clinical Team Leader (HFD-510)
and
Joy D. Mele, M.S., Statistical
Reviewer (HFD-715)
Subject: Mevacor OTC NDA
21213
This
memorandum addresses Section 1.6.1.2.5 entitled “Defining the Benefit of
Lovastatin 20 mg once daily in the Mevacor OTC Eligible Population”.
The
applicant (Merck Research Laboratories) performed analyses of the
AFCAPS/TEXCAPS data to estimate the possible effect of 20 mg (the proposed OTC dose) of lovastatin on
clinical endpoints in an OTC eligible population. The selection criteria for
AFCAPS/TEXCAPS and the OTC-eligible
population are summarized in Table 1.
Table 1. Selection criteria for Study
AFCAPS/TEXCAPS and the proposed
OTC-eligible population
|
AFCAPS/TEXCAPS |
OTC-eligible |
Age |
Male³45; Female³55 |
Male³45; Female³55 |
LDL-C |
125-129 if TC/HDL>6 130-190 |
130-170 |
Risk factors
HDL
smoker
family history
high BP |
Must have low HDL Male £45; Female£55 yes yes controlled BP only |
At least one risk factor <40 yes yes yes |
Evidence of CVD |
Excluded |
Excluded |
The
primary difference between the criteria is that AFCAPS/TEXCAPS
patients all had “low” HDL while the OTC patients must have at least one risk factor
which may or may not include low HDL.
Reviewer’s Comments:
The results of AFCAPS/TEXCAPS may
not be applicable to patients who do not have low HDL; however, evidence from
the Heart Protection Study suggests that similar patients without evidence of cardiovascular disease who have high HDL and
a risk factor for CHD (such as diabetes, hypertension or peripheral/cerebral
vascular disease) receive beneficial effects from statin therapy.
The
applicant looked at three subgroups of patients from AFCAPS/TEXCAPS; 1)
patients meeting the OTC eligible criteria at baseline, 2) patients who reached
goal without titrating up to 40 mg and 3) patients who achieved an LDL of less
than 130 on treatment (these groups are described in more detail in Dr. Parks’
review ).
Reviewer’s Comments:
Patients in Groups 2 and 3 were selected based on their response and so those groups do not represent proper subgroups (i.e. randomized groups); therefore, the results of Groups 2 and 3 are not reviewed here. The drawback to Group 1 is that about ½ the patients were titrated to the 40 mg dose. In fact the applicant stated that because of the titration, “direct estimation of the benefit of 20 mg … is not possible” (page D-61 of the NDA).
The
results for the OTC eligible subgroup and the complete AFCAPS/TEXCAPS
population from the NDA under review (2004) and from a previous submission
dated
Table 2. AFCAPS/TEXCAPS Event rates and
Number-Needed-to-Treat (NNT) as reported by the applicant in NDA’s submitted in
1999 and 2004
|
Placebo |
Lovastatin |
NNT |
1999 NDA |
|||
All Pts
Events
5 YR K-M rate
OTC- Eligible
Events
5 YR K-M rate |
183/3301 5.2% 108/1921 5.3% |
116/3304 3.3% 60/1884 3.0% |
54 43 |
2004 NDA |
|||
All Pts
Events
6 YR K-M rate
OTC- Eligible
Events
6 YR K-M rate |
184/3301 6.8% 88/1449 7.5% |
116/3304 3.8% 48/1433 3.5% |
34 25 |
FDA review of AFCAPS/TEXCAPS
All Pts. Events End of Study K-M Rate |
183/3301 7.2% |
116/3304 5.1% |
48 |
Event=cardiac
death, fatal or non-fatal MI or unstable angina
Reviewer’s Comments:
The difference
between the rates and the NNT in the above table is due to the length of
observation periods; the 1999 rates were based on 5 year estimates while 2004
rates are based on 6-year estimates. The last row shows the Kaplan-Meier
estimates presented in the FDA review of AFCAPS/TEXCAPS which is much closer to
the 5-year treatment effect. It is worth noting that there were only two centers
in AFCAPS/TEXCAPS and one center (with 43% of the patients) had a maximum
follow-up of 5.1 years. A small number of patients completed 6 years of
treatment. This reviewer concludes that the NNT estimates presented in the
submission under review (the 2004 submission) are not acceptable and
underestimate the NNT.
Overall this reviewer thinks that there is a body of evidence from several statin trials that suggest that a wide range of patients may receive clinical benefit from statin therapy; however, none of the clinical endpoint trials were conducted in a population limited to Merck’s targeted OTC population and treated with only 20 mg of Mevacor. Also as mentioned by FDA reviewer David Hoberman in a statistical review of the 1999 NDA, a critical factor to consider is that “the compliance in AFCAPS/TEXCAPS is probably much greater than that in a true OTC setting.” Estimates from a closely monitored population may not represent what we could expect in an OTC population.